Indian Clarity

Light. Truth. Clarity.

Loading ad...
Sports

Report: Nikola Topic completes chemotherapy for testicular cancer

Story bySep 29, 2025; Oklahoma City, OK, USA; Oklahoma City Thunder guard Nikola Topic poses for a photo during the 2025 Oklahoma City Thunder media day at Paycom Center. Mandatory Credit: Alonzo Adams-Imagn ImagesClemente Almanza, OKC Thunder WireFri, January 9, 2026 at 2:45 AM UTC·1 min readContinuing to ramp up his pregame warmup activity, Nikola Topic cleared a major hurdle for his eventual NBA debut. His agent, Misko Raznatovic, recently told Serbia's Arena Sport TV that he has completed his chemotherapy for his testicular cancer."The chemotherapy was successfully completed, and he is now returning to the training process, although he was active during the therapy as well," Raznatovic said.

Report: Nikola Topic completes chemotherapy for testicular cancer

Credit: Yahoo

Key Highlights

  • "It's hard to pinpoint a timeline, but I sincerely hope he gets minutes this year, not only in the G League but on the NBA floor as well, if everything goes the way it is right now."AdvertisementAdvertisementAdvertisementThe Oklahoma City Thunder have fully supported Topic since his testicular cancer diagnosis in Oct.
  • 2025.
  • After playing in the 2025 Summer League and one preseason game, he underwent surgery to determine if he had cancer.
  • That turned out to be the case, as Sam Presti told the media. Presti said that Topic's medical group was confident he'd beat it with chemotherapy and eventually return to basketball activities.
  • He also noted that testicular cancer is one of the more curable forms of male cancer. Over the last month, Topic has participated in pregame warmups.
Loading ad...

Sources

  1. Report: Nikola Topic completes chemotherapy for testicular cancer

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.

Related Stories

Loading ad...